Literature DB >> 7395817

Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III.

H Bounameaux, G A Marbet, B Lämmle, R Eichlisberger, F Duckert.   

Abstract

Three laboratory methods for monitoring heparin treatment have been compared using 63 plasma samples: the thrombin time, the activated partial thromboplastin time, and the measurement of the heparin concentration using a chromogenic substrate. A good correlation was found between the methods. However, the intensity of anticoagulation was identical in only 27 of the 63 samples (43%) when the thrombin time and the activated partial thromboplastin time were compared. Fully discordant results were recorded for four samples (6%). The thrombin time was found to be more closely related to the plasma heparin concentration than was the activated partial thromboplastin time. Both antithrombin-III activity and immunologic levels were lower in the group with strong heparinization. It is suggested that the thrombin time is a good and safe method for monitoring heparin treatment.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7395817     DOI: 10.1093/ajcp/74.1.68

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  Heparin 1986. Indications and effective use.

Authors:  P Ockelford
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

Review 2.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

3.  Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions.

Authors:  Susanne Bürki; Béatrice Brand; Robert Escher; Walter A Wuillemin; Michael Nagler
Journal:  BMJ Open       Date:  2018-06-09       Impact factor: 2.692

4.  Enhanced Antiviral Function of Magnesium Chloride-Modified Heparin on a Broad Spectrum of Viruses.

Authors:  Kemal Mese; Oskar Bunz; Wolfram Volkwein; Sahithya P B Vemulapalli; Wenli Zhang; Sebastian Schellhorn; Kristin Heenemann; Antje Rueckner; Andreas Sing; Thomas W Vahlenkamp; Anna-Lena Severing; Jian Gao; Malik Aydin; Dominik Jung; Hagen S Bachmann; Kurt S Zänker; Ulrich Busch; Armin Baiker; Christian Griesinger; Anja Ehrhardt
Journal:  Int J Mol Sci       Date:  2021-09-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.